Continuity of care for patients with de novo metastatic cancer during the COVID‐19 pandemic: A population‐based observational study
Ellis Slotman,Feike Weijzen,Heidi P. Fransen,Jolanda C. van Hoeve,Auke M. T. Huijben,Evelien J. M. Kuip,Agnes Jager,Peter W. A. Kunst,Hanneke W. M. van Laarhoven,Jolien Tol,Vivianne C. G. Tjan‐Heijnen,Natasja J. H. Raijmakers,Yvette M. van der Linden,Sabine Siesling,On‐behalf‐of‐the‐COVID‐and‐Cancer‐NL Consortium
DOI: https://doi.org/10.1002/ijc.34857
2024-01-26
International Journal of Cancer
Abstract:What's new? During the COVID‐19 pandemic, about one‐fifth of cancer patients in the Netherlands experienced changes in treatment, including delays and discontinuation. In this study, data from the Netherlands Cancer Registry was examined to better understand the impact of the COVID‐19 pandemic specifically on the treatment of patients with metastatic cancer. Comparison of data before and during the pandemic revealed no delays and only minor changes in metastatic cancer treatment during the pandemic. Moreover, time between diagnosis and treatment initiation shortened during the pandemic, suggesting that regular and timely cancer care was provided despite increased pressure on the country's healthcare system. During the COVID‐19 pandemic recommendations were made to adapt cancer care. This population‐based study aimed to investigate possible differences between the treatment of patients with metastatic cancer before and during the pandemic by comparing the initial treatments in five COVID‐19 periods (weeks 1–12 2020: pre‐COVID‐19, weeks 12–20 2020: 1st peak, weeks 21–41 2020: recovery, weeks 42–53 2020: 2nd peak, weeks 1–20 2021: prolonged 2nd peak) with reference data from 2017 to 2019. The proportion of patients receiving different treatment modalities (chemotherapy, hormonal therapy, immunotherapy or targeted therapy, radiotherapy primary tumor, resection primary tumor, resection metastases) within 6 weeks of diagnosis and the time between diagnosis and first treatment were compared by period. In total, 74,208 patients were included. Overall, patients were more likely to receive treatments in the COVID‐19 periods than in previous years. This mainly holds for hormone therapy, immunotherapy or targeted therapy and resection of metastases. Lower odds were observed for resection of the primary tumor during the recovery period (OR 0.87; 95% CI 0.77–0.99) and for radiotherapy on the primary tumor during the prolonged 2nd peak (OR 0.84; 95% CI 0.72–0.98). The time from diagnosis to the start of first treatment was shorter, mainly during the 1st peak (average 5 days, p
oncology